Knights of Columbus Asset Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-32,622	Closed	-$903K	–	397
2025 Q2	$903K	Sell	32,622 -30,002	-48%	-$764K	0.05%	251
2025 Q1	$1.39M	Buy	62,624 +1,658	+3%	+$34.1K	0.1%	216
2024 Q4	$1.21M	Sell	60,966 -11,790	-16%	-$269K	0.08%	230
2024 Q3	$1.82M	Sell	72,756 -93,516	-56%	-$2.28M	0.12%	194
2024 Q2	$3.09M	Buy	166,272 +3,989	+2%	+$74.7K	0.2%	167
2024 Q1	$3.2M	Buy	+162,283	New	+$3.17M	0.23%	151

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Knights of Columbus Asset Advisors's KNSA Position: Q3 2025 in Review

Knights of Columbus Asset Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 32,622 shares — an estimated $903K sold.

Knights of Columbus Asset Advisors first reported a position in KNSA in Q1 2024 and held it in 6 quarters. The position peaked at $3.2M in Q1 2024. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

Knights of Columbus Asset Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 32,622 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $903K.
Knights of Columbus Asset Advisors first reported a position in Kiniksa Pharmaceuticals in Q1 2024 and held it in 6 quarters.
Knights of Columbus Asset Advisors's Kiniksa Pharmaceuticals position peaked at $3.2M in Q1 2024.
204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Knights of Columbus Asset Advisors's 13F filing for Q3 2025, filed 3 Nov 2025.